Clinical Study of MAK Immune Cells in the Treatment of PHC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral blood mononuclear cells were obtained and then the MAK(Mixed-activated Killer) cells were injected, and then the safety and efficacy were observed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy

NCT01760616

Hepatic Carcinoma

TERMINATED PHASE4

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

NCT01770431

Hepatic Carcinoma

COMPLETED PHASE4

Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC

NCT06900478

Hepatocarcinoma

NOT_YET_RECRUITING PHASE2

Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors

NCT07337460

Hepatocellular Carcinoma (HCC)

RECRUITING PHASE2

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

NCT00283478

Non-Small Cell Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral venous blood was collected twice (50-60ml/time, 2 times, 1 week apart) from each patient. Peripheral blood mononuclear cells were separated, induced, expanded, and cultured in vitro for a total of 1 week to obtain physiological conditions Immune cell populations with tumor-killing activity (mainly MAK immune cells mainly CD3-CD16 + CD56 + and CD3 + CD56 +), and then the MAK(Mixed-activated Killer) cells were injected intravenously for three days. Observe that the patient received cell therapy 24h, The safety and efficacy of 1 month, 2 months, and 3 months, and monitoring of adverse reactions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

To evaluate the safety and reliminary efficacy of MAK immune cells in the treatment of PHC.

To evaluate the safety and reliminary efficacy of MAK immune cells in the treatment of primary hepatocellular carcinoma.

Group Type EXPERIMENTAL

Mixed-activated Killer Immune Cells

Intervention Type OTHER

Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mixed-activated Killer Immune Cells

Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age over 18 years old, regardless of gender.
2. Patients with primary hepatocellular carcinoma.
3. According to the "Regulations for Diagnosis and Treatment of Primary Liver Cancer (2019 Edition)" by the Health Commission of the People's Republic of China Liver cancer staging scheme, patients with Ⅲa and Ⅲb.
4. The expected survival time is ≥6 months.
5. Peripheral blood white blood cell count ≥3×10\^9 /L.
6. Understand and voluntarily sign the informed consent form.

Exclusion Criteria

1. Patients with immunodeficiency or autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, multiple Primary sclerosis, insulin dependent diabetes, etc.).
2. Patients with a history of other malignant tumors in the past 5 years.
3. Patients who participated in other clinical trials or clinical research treatments within 3 months before this clinical study By.
4. Patients who have received other cell therapy within the past 6 months.
5. Patients with fever who have not effectively controlled the infection.
6. Patients with high allergies or a history of severe allergies.
7. Patients who are allergic to albumin.
8. Patients after organ transplantation; patients who have been using or are using immunosuppressive agents for a long time.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No